Download PDF
Review  |  Open Access  |  21 Nov 2023

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Views: 416 |  Downloads: 94 |  Cited:   0
Cancer Drug Resist 2023;6:805-27.
10.20517/cdr.2023.77 |  © The Author(s) 2023.
Author Information
Article Notes
Cite This Article


Cancer drug resistance has become one of the main challenges for the failure of chemotherapy, greatly limiting the selection and use of anticancer drugs and dashing the hopes of cancer patients. The emergence of supramolecular host-guest nanosystems has brought the field of supramolecular chemistry into the nanoworld, providing a potential solution to this challenge. Compared with conventional chemotherapeutic platforms, supramolecular host-guest nanosystems can reverse cancer drug resistance by increasing drug uptake, reducing drug efflux, activating drugs, and inhibiting DNA repair. Herein, we summarize the research progress of supramolecular host-guest nanosystems for overcoming cancer drug resistance and discuss the future research direction in this field. It is hoped that this review will provide more positive references for overcoming cancer drug resistance and promoting the development of supramolecular host-guest nanosystems.


Supramolecular nanosystems, host-guest interaction, cancer drug resistance


With the number of cancer cases increasing each year, cancer has become the second leading cause of death worldwide[1]. Although chemotherapy remains the primary method of cancer treatment, its effectiveness is severely limited by cancer drug resistance[2-5]. The occurrence of cancer drug resistance is associated with multiple factors, including the overexpression of multidrug resistance gene (MDR1), anti-apoptotic protein (BCL-2), multidrug resistance-associated protein (MRP), and the enhanced activity of glutathione S-transferase (GST) and DNA repair enzyme[6-8]. These factors can lead to decreased drug uptake, increased drug efflux, DNA damage repair, abnormal drug metabolism, and dysfunctional apoptosis, resulting in cancer drug resistance[9,10]. Nanosystems have been widely used to overcome cancer drug resistance due to their ability to alter the way drugs enter cells, increase drug uptake, and improve drug stability[11,12]. Common nanosystems used to overcome cancer drug resistance include liposomes, polymeric nanoparticles, and metal nanoparticles. However, there are still some problems in the application of these nanosystems. For example, drugs loaded in liposomes tend to leak in the circulatory system before reaching the tumor; polymeric nanoparticles have a high burst release effect; and metal nanoparticles have poor biocompatibility. These problems have led to the limited role of these nanosystems in overcoming cancer drug resistance[13,14]. Therefore, it is urgent to develop a class of novel nanosystems to reverse cancer drug resistance.

Supramolecular chemistry is “chemistry beyond the molecule”[15]. Supramolecules generally refer to organized aggregates formed by non-covalent interactions of two or more molecules, including electrostatic interaction, hydrogen bond, van der Waals force, and π-π interaction[16-21]. By introducing supramolecules into the nanosystem, it is possible to construct a more promising new drug delivery system, supramolecular host-guest nanosystem, which provides a potential solution for cancer drug resistance[22-28]. Compared with traditional nanomaterials constructed by covalent interactions, supramolecular host-guest nanomaterials constructed by non-covalent interactions have excellent dynamic reversibility and responsiveness to various stimuli (such as weak acidity, specific enzymes, and different redox environments)[29-33]. Based on these advantages, supramolecular host-guest nanosystems can increase drug uptake, accurately release drugs, inhibit drug efflux, and protect the activity of drugs, which provide great possibilities for eliminating cancer drug resistance and promoting the progress of cancer treatment[34-37].

In this review, we summarize the research progress of supramolecular host-guest nanosystems for overcoming cancer drug resistance over the past few years, including cyclodextrins, calixarenes, cucurbiturils, and pillararenes [Scheme 1]. Moreover, the challenges and prospects of supramolecular host-guest nanosystems for overcoming cancer drug resistance are discussed extensively. This review aims to provide valuable insights and contribute to the development of more effective ways to reverse cancer drug resistance.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Scheme 1. Supramolecular host-guest nanosystems for overcoming cancer drug resistance. GSH: Glutathione; GST: glutathione S-transferase.


Cyclodextrins (CDs), a class of natural oligosaccharides obtained from the degradation of starch, are linked by glucopyranose units through α-1,4-glycosidic bonds [Figure 1][38,39]. The most common CDs contain six, seven, and eight glucopyranose units, respectively, known as α, β, and γ-CDs[40,41]. CDs have hydrophobic cavities, which can encapsulate hydrophobic drug molecules to form host-guest complexes[42-45]. In addition, these complexes can self-assemble into nanoparticles, greatly improving the efficiency of the drug (such as good water solubility, high stability, and low physiological toxicity)[46-48]. Therefore, CDs-based host-guest nanosystems have the potential to reverse cancer drug resistance by increasing drug uptake and decreasing drug efflux[49-51]. For example, Yang et al. constructed three nanomedicines based on β-CDs that enhanced the drug uptake and the toxicity of drug-resistant cells[52]. Das et al. prepared a dual-responsive nanocarrier by embedding carbon nanotubes into β-CDs-based polymers, enabling the combination of cocktail chemotherapy with photothermal therapy, which was conducive to multidrug resistance reversal[53].

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 1. Schematic illustration of structures of (A) CDs; (B) calixarenes (C[n]As); (C) cucurbiturils (CB[n]s); and (D) pillararenes (P[n]As).

P-glycoprotein (P-gp) is an energy-dependent efflux pump located on the cell membrane[54,55]. P-gp depends on the energy produced by ATP hydrolysis within the mitochondria to keep intracellular drug concentrations low by transporting drug molecules outside the cell, resulting in drug resistance[56-58]. Therefore, drug resistance can be effectively reversed by inducing mitochondrial dysfunction. Wang et al. constructed a nanosystem (Aa-DOX + ADD@PC) based on a pH-sensitive graft copolymer (PBAE-g-β-CD) to achieve co-loading of the anticancer drug doxorubicin (DOX) and mitochondrial inhibitor (ADD) [Figure 2A][59]. When Aa-DOX + ADD@PC was endocytosed by tumor cells, DOX and ADD were released in the acidic environment for combined chemotherapy. Western blot assay was used to study the expression levels of P-gp and X-linked inhibitor of apoptosis protein (XIAP), and it was found that Aa-DOX + ADD@PC showed the best inhibitory effect on P-gp and XIAP [Figures 2B and C]. Moreover, the therapeutic effect of Aa-DOX + ADD@PC was better than that of free DOX, significantly inhibiting the growth of drug-resistant tumors [Figure 2D]. In this work, the effective loading of mitochondrial inhibitors by CDs was used to successfully reverse drug resistance by decreasing drug efflux, providing a new therapeutic platform for overcoming multidrug resistance (MDR).

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 2. (A) Schematic illustration of dual-drug co-loaded nanoparticle (Aa-DOX + ADD@PC) for overcoming cancer drug resistance; The expression levels of (B) P-gp and (C) XIAP in MCF-7/ADR cells with different treatments; (D) Tumor growth inhibition curves of tumor-bearing mice after various formulations. (*P < 0.05) This figure is quoted with permission from Wang et al.[59]. ADD: Mitochondrial inhibitor; DOX: doxorubicin; XIAP: X-linked inhibitor of apoptosis protein.

Furthermore, compared with free drugs, tumor cells can effectively take up nanomedicine, which is conducive to the reversal of drug resistance caused by low intracellular drug concentration[60,61]. Liu et al. developed pH/redox dual-responsive DOX delivery nanosystems (DOX@RPMSNs) based on cationic β-cyclodextrin-PEI (PEI-β-CD) to overcome drug resistance of tumor cells [Figure 3A][62]. The poly (ethylene glycol) amine derivative shell (PEG-b-PLLDA) of DOX@RPMSNs could protect DOX@RPMSNs from safely reaching the vicinity of tumor cells, increasing the absorption of drugs by tumor cells. PEI-β-CD and DOX were sequentially released in response to the action of acid and glutathione (GSH) in tumor cells. DOX was used to kill tumor cells, and PEI-β-CD acted as an inhibitor to downregulate the expression of drug resistance-related P-gp by reducing ATP [Figure 3B]. Compared with other formulations, DOX@RPMSNs significantly inhibited tumor growth [Figures 3C and D]. These results indicated that DOX@RPMSNs successfully improved drug resistance reversal.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 3. (A) Schematic illustration of the construction of sequentially responsive nanosystem (DOX@RPMSNs) and dual-responsive drug release; (B) Total ATP concentrations of MCF7/ADR cells treated with H2O2 and different doses of RPMSNs; (C) The expression levels of P-gp in tumor cells with different treatments; (D) Changes of tumor volume in tumor-bearing mice with different treatments (*P < 0.05,**P < 0.01, ***P < 0.001). This figure is quoted with permission from Liu et al.[62]; (E) Schematic illustration of the construction of co-delivery nanosystem (HPMSNs) and dual-responsive drug release; (F) The expression levels of P-gp and GCN5 in tumor cells with different treatments; (G) Changes of tumor weight in tumor-bearing mice with different treatments (*P < 0.05, **P < 0.01). This figure is quoted with permission from Yuan et al.[68]. DOX: Doxorubicin; PEG-b-PLLDA: poly (ethylene glycol) amine derivative shell.

Histone-acetyltransferase (GCN5) is a silencing protein closely related to drug-resistance genes. Drug resistance caused by efflux can be reversed by down-regulating the expression of GCN5[63,64]. RNA interference (RNAi) is a therapeutic technique that specifically targets mRNA and regulates the expression of silencing proteins[65-67]. Yuan et al. exploited a nanosystem (DOX/siRNA@HPMSNs) to combine RNAi and DOX, which could knockout drug-resistance genes (Figure 3E)[68]. The hyaluronan (HA) shell of DOX/siRNA@HPMSNs could prolong the circulation time of DOX/siRNA@HPMSNs in vivo and target tumor cells, which promoted the accumulation of antitumor drugs. In the microenvironment of tumor cells, the effective release of siRNA could downregulate the expression of GCN5 to reduce the efflux of DOX caused by P-gp [Figure 3F]. Additionally, the inhibition rate of DOX/siRNA@HPMSNs on the growth of drug-resistance tumors was higher than DOX by evaluating the chemotherapeutic effects of different drug delivery systems [Figure 3G]. The two pH/redox dual-responsive nanosystems reduced drug efflux caused by the overexpression of P-gp in different ways, providing more possibilities for reversing MDR.

The acidic tumor microenvironment commonly found in solid tumors can reduce the endocytosis of free drugs and dissociate drug molecules[69,70]. Therefore, pH-responsive supramolecular host-guest nanosystems have been widely developed to enhance cell internalization and protect drugs from dissociation[71-73]. He et al. prepared a pH-responsive nanoparticle (Ac-α-CD NP) based on acetylated α-CD (Ac-α-CD), which could stably encapsulate paclitaxel (PTX) [Figure 4A][74]. Ac-α-CD NP had a stronger inhibitory effect on the viability of breast cancer drug-resistant cells (MDA-MB-231) compared with free PTX and PLGA NPs [Figure 4B]. Moreover, Ac-α-CD NP exhibited good drug activity at a low concentration (0.854 nM), indicating its potential to kill drug-resistant cells.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 4. (A) Schematic illustration of the formation of pH-sensitive nanosystems (Ac-α-CD NP); (B) The cell viability of MDA-MB-231 cells treated with different doses of PTX, PLGA NP, and Ac-α-CD NP (**P < 0.01). This figure is quoted with permission from He et al.[74]; (C) Schematic illustration of the antitumor progress of Ac-α-CD NP in MCF-7/ADR cells; (D) The P-gp expression level; and (E) the accumulation of DOX with different doses of Ac-α-CD NP in MCF-7/ADR cells (*P < 0.05, **P < 0.01). This figure is quoted with permission from Shi et al.[75]. CD: Cyclodextrin; DOX: doxorubicin; NP: nanoparticle; PTX: paclitaxel.

Additionally, further studies showed that Ac-α-CD NP could also enhance the uptake and sensitivity of drug-resistant cells to DOX [Figure 4C][75]. α-CD was released by pH-induced hydrolysis of Ac-α-CD NP to inhibit the expression of P-gp and decrease the activity of ATPase, eliminating drug resistance caused by drug efflux [Figure 4D]. The changes in drug concentrations indicated that the downregulation of P-gp expression directly increased the accumulation of DOX in drug-resistant cells, thus achieving the purpose of inhibiting cancer drug resistance [Figure 4E]. Such pH-responsive supramolecular nanoparticles could not only inhibit the viability of drug-resistant cells at low concentrations but also increase the uptake and sensitization of drug-resistant cells to DOX, successfully reversing drug resistance from multiple angles.

Various star-shaped polymers can be obtained by modifying β-CD with different polymer chains[76,77]. These polymers can further self-assemble into stable supramolecular host-guest nanoparticles after loading anticancer drugs[78-80]. Compared with free drugs, nanoparticles are more easily internalized by tumor cells, reducing the efflux of drugs[81-83]. These factors work together to eliminate cancer drug resistance[84,85]. Chen et al. constructed a cationic β-CD-based nanocarrier that co-delivered PTX and Nur77 gene (an orphan nuclear receptor) to eliminate cancer drug resistance[86]. In addition, they reported a nanoparticle based on a PEGylated star-shaped copolymer successfully reversed MDR1-induced drug resistance[87].

Subsequently, they designed a new type of thermosensitive star-shaped polymer β-CD-g-(PEG-v-PNIPAAm)7 with “V”-shaped arms, which encapsulated PTX through the cavity of β-CD [Figure 5A][88]. The drug-loaded polymer further self-assembled into a stable supramolecular host-guest nanomedicine at 37 °C, greatly enhancing the retention of drugs in cells. Compared with other drugs, this supramolecular host-guest nanomedicine was more sensitive to the change of temperature, causing a sharp decline in cell viability at 37 °C [Figure 5B]. When the drug-resistance tumor was transplanted into mice and treated with PTX and nanomedicine, respectively, β-CD-g-(PEG-v-PNIPAAm)7/PTX was more prominent in reducing cell viability [Figure 5C]. Additionally, there was no obvious change in tumor volume after treatment with β-CD-g-(PEG-v-PNIPAAm)7/PTX [Figure 5D]. These results indicated that β-CD-based temperature-responsive nanomedicine had a good therapeutic efficacy against drug-resistant tumors.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 5. (A) Schematic illustration of supramolecular nanoparticle for inhibiting pump-mediated drug resistance; (B) Cell viability of HepG2/MDR1 cells treated with β-CD-g-(PEG-v-PNIPAAm)7, PTX, and β-CD-g-(PEG-v-PNIPAAm)7/PTX at different temperatures; (C) Changes in cell viability of HepG2/MDR1 cells treated with different doses of PTX and β-CD-g-(PEG-v-PNIPAAm)7/PTX; (D) Tumor growth inhibition curves of tumor-bearing mice after various treatments (*P < 0.05). This figure is quoted with permission from Fan et al.[88]. CD: Cyclodextrin; MDR1: multidrug resistance gene; PEG: poly (ethylene glycol); PTX: paclitaxel.

Moreover, Li et al. constructed a unimolecular micelle based on a star-shaped polymer (β-CD-g-PCL-SS-PEG-FA) that stably encapsulated DOX [Figure 6A][89]. The folic acid (FA) in the unimolecular micelle could target and penetrate tumor cells to increase the accumulation of DOX, inhibiting the cancer drug resistance caused by decreased drug uptake. The drug loaded in the unimolecular micelle could be released in response to GSH. MTT assay analysis indicated that β-CD-g-PCL-SS-PEG-FA had a better inhibitory effect on cell viability compared with free DOX [Figure 6B and C]. In addition, the overexpression of folate receptors on cervical cancer drug-resistant cells (HeLa/MDR1) accelerated the uptake of β-CD-g-PCL-SS-PEG-FA, enhancing the therapeutic effect of DOX on drug-resistant cells. Such β-CD-based stimuli-responsive supramolecular host-guest nanoparticles showed exciting results in overcoming cancer drug resistance due to the precise targeting, effective uptake, and controlled release of drugs.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 6. (A) Schematic illustration of a unimolecular micelle for inhibiting pump-mediated drug resistance; Cell viability of (B) HepG2/MDR1 cells and (C) HeLa/MDR1 cells treated with different doses of DOX, β-CD-g-PLC-SS-PEG/DOX, and β-CD-g-PLC-SS-PEG-FA/DOX. This figure is quoted with permission from Li et al.[89]. CD: Cyclodextrin; DOX: doxorubicin; FA: folic acid; GSH: glutathione; MDR1: multidrug resistance gene; PEG: poly (ethylene glycol).


Calixarenes are a class of cyclic oligomers formed by methylene-bridging ortho-phenolic hydroxyl groups [Figure 1B][90-92]. Due to their molecular shapes similar to the Sangreal, they are named calix[n]arenes (C[n]As) by Gutsche[93]. By introducing hydrophilic and hydrophobic groups at the upper and lower rims of C[n]As, respectively, amphiphilic C[n]As can be designed, which are easy to self-assemble into vesicles, nanoparticles, or other aggregates[94-99]. Host-guest nanosystems based on C[n]As have low toxicity and good biocompatibility, becoming a new research hotspot in the field of cancer drug resistance[100-102].

The close coordination between GSH and GST can initiate detoxification mechanisms within tumor cells, leading to the formation of drug resistance[103-105]. For example, GST can catalyze the binding of GSH to electrophilic antitumor drugs, accelerating the degradation of drugs[106-108]. Therefore, drug resistance can be reversed by regulating the GST. Recently, Dai et al. designed a nanomedicine (Pt-cCAV5-FU) based on sulfonatocalix[4]arene for overcoming GST-induced cancer drug resistance [Figure 7A][109]. The GST regulator (5-FU) was encased into the hydrophilic core of Pt-cCAV5-FU self-assembled from a host-guest complex of sulfonatocalix[4]arene with cisplatin. Pt-cCAV5-FU actively released cisplatin and 5-FU during the hydrolysis process caused by esterase. 5-FU could downregulate GST activity, prompting cisplatin to damage DNA rather than binding to GSH [Figure 7B]. In addition, the endocytosis of cisplatin resistance cells A549/CDDP against Pt-cCAV5-FU was stronger than that of A549, which increased the accumulation of cisplatin in cancer cells [Figure 7C]. All of these factors ultimately made Pt-cCAV5-FU more toxic to drug-resistance cells. This work developed a novel nanomedicine, laying the foundation for C[n]As-based host-guest nanosystems to reverse cisplatin resistance.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 7. (A) Schematic illustration of Pt-cCAV5-FU for overcoming cisplatin resistance in A549/CDDP cells; (B) The GST activity of A549/CDDP cells with different treatments; (C) Platinum content in the genomic DNA of A549 and A549/CDDP cells after incubation with Pt-cCAV and Pt-cCAV5-FU for 12 h. This figure is quoted with permission from Dai et al.[109]. GSH: Glutathione; GST: glutathione S-transferase.

Furthermore, although free DOX can kill the nuclear DNA (n-DNA) of tumor cells, the undamaged mitochondrial DNA (Mt-DNA) can trigger drug resistance[110-112]. Therefore, the design of a drug to destroy synchronously n-DNA and Mt-DNA can promote the reversal of drug resistance[113]. Nair et al. constructed a gold nanotherapy platform (TTNDV) based on sulfonatocalix[4]arene [Figure 8A][114]. The nanoplatform could encapsulate DOX and mitochondrion-targeted analogue (Mt-DOX) in an optimal ratio of 1:100 to reverse cancer drug resistance caused by mitochondrial escape. In vitro and in vivo experiments showed that TTNDV had less toxic side effects than free DOX. In addition, TTNDV had a stimulating response to temperature. Under near-infrared irradiation, drugs embedded in TTNDV were released simultaneously to kill n-DNA and Mt-DNA, successfully overcoming DOX resistance and improving the chemotherapeutic effect of DOX [Figure 8B]. This work solved the problem of DOX resistance by killing Mt-DNA to induce apoptosis, providing a feasible strategy for reversing cancer drug resistance.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 8. (A) Schematic illustration of TTNDV to overcome cancer drug resistance by killing n-DNA and Mt-DNA; (B) Tumor growth inhibition curves of tumor-bearing mice after different formulations (*P < 0.05). This figure is quoted with permission from Nair et al.[114]. DOX: Doxorubicin; FA: folic acid.


Cucurbiturils (CB[n]s) are a kind of macrocyclic hosts constructed by condensation of glycoluril with formaldehyde under acid conditions, which are the fourth macrocyclic hosts after crown ethers, cyclodextrins, and calixarenes [Figure 1C][115-117]. According to the different number of glycoluril units, different types of CB[n]s can be obtained, and common cucurbiturils include CB[6], CB[7], and CB[8][118,119]. Due to their unique structures of hydrophobic cavity and hydrophilic port, CB[n]s are easy to form host-guest complexes with drug molecules and are promising materials for reducing side effects and enhancing the stability of antitumor drugs[120-124]. In addition, CB[n]s-based supramolecular nanosystems can be used to effectively reverse cancer drug resistance[125-128].

Cancer drug resistance is closely related to the inhibition of tumor apoptosis[129,130]. Mitochondria serves as the center for regulating tumor cell apoptosis[131,132]. Therefore, the destruction of mitochondria is also an effective way to overcome cancer drug resistance[133-135]. Recently, Dai et al. synthesized a multivalent supramolecular polymer (HABMitP) by modifying HA with mitochondrial targeting peptide and 4-bromophenylpyridium [Figure 9A][136]. The combination of HABMitP, cisplatin, and CB[8] could promote mitochondrial aggregation, which led to the deterioration of mitochondria to release apoptosis-inducing factor (cytochrome C), thereby activating the apoptosis of tumor cells [Figure 9B and C]. Moreover, cisplatin-resistant tumors did not grow treated with CisPt + HABMitP + CB[8] for 14 days, indicating that assembly-induced mitochondrial aggregation significantly improved the antitumor efficacy of cisplatin [Figure 9D]. This study showed that the regulation of mitochondrial behavior was beneficial to the reversal of drug resistance, which provided a broad prospect for overcoming tumor drug resistance.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 9. (A) Schematic illustration of mitochondrial aggregation progress after treatment with multivalent supramolecular polymer (HABMitP) and CB[8]; (B) The ratio of cytosol cytochrome C [Cyt C(cyto)] to mitochondrial cytochrome C [Cyt C(mit)] and (C) The apoptosis percentage of TUNEL-positive cells with different treatments; (D) Changes of tumor volume in tumor-bearing mice with different formulations (*P < 0.05). This figure is quoted with permission from Dai et al.[136].

The inhibition of P-gp expression by reducing ATP concentration can reduce drug resistance in tumor cells[137,138]. Wang et al. reported nanoparticles (SCC-NPs) based on CB[7], which encapsulated the anticancer drug oxaliplatin (OxPt) and mitochondria-targeting peptide (N-Phe-KLAK) by the excellent host-guest properties of CB[7] [Figure 10A][139]. Due to the special acid responsiveness and competitiveness of the polymeric shell, SCC-NPs were used for self-motivated supramolecular combination chemotherapy. In acidic tumor environments, the amidomethyl phenylamine moieties on the polymeric shell were restored to form host-guest complexes with CB[7], competing to replace and release OxPt and N-Phe-KLAK. The released N-Phe-KLAK could effectively inhibit the production of ATP, resulting in the damage of energy-dependent drug efflux pump [Figure 10B]. Additionally, the accumulation of OxPt in cells directly led to an increase in the number of apoptotic cancer cells, which successfully inhibited the viability of drug-resistance cells [Figure 10C and D). Self-motivated supramolecular combination chemotherapy provided a new strategy for addressing the issue of cancer drug resistance.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 10. (A) Schematic illustration of the preparation and mechanism of self-motivated nanoparticles (SCC-NPs) in overcoming drug resistance; (B) ATP levels in HCT116/OxPt cells treated with Ctr NPs and SCC NPs at different doses; (C) The number of apoptotic cells treated with different formulations; (D) Cell viability of HCT116/OxPt cells after incubating with different treatments (***P < 0.001). This figure is quoted with permission from Wang et al.[139]. PEG: Poly (ethylene glycol).

The Fusobacterium nucleatum (F. nucleatum) with apoptosis-inhibiting effect can trigger drug resistance in colorectal cancer (CRC) cells[140-143]. To address this issue, Yan et al. constructed a CB[7]-based nanomedicine (PG-Pt-LA/CB[7]) by multiple assemblies to overcome drug resistance [Figure 11A][144]. PG-Pt-LA/CB[7] targeted and penetrated cancer cells and released OxPt in response to the GSH. The efficient uptake and stable release of drugs increased the accumulation of OxPt in CRC cells. In addition, PG-Pt-LA/CB[7] showed the best inhibition effect on F. nucleatum compared to OxPt and PG-Pt-LA, successfully overcoming the drug resistance of CRC cells caused by F. nucleatum [Figure 11B]. A negligible growth in tumor volume was observed after 18 d of incubating tumors with PG-Pt-LA/CB[7], showing that PG-Pt-LA/CB[7] improved the chemotherapeutic effect of OxPt on CRC cells [Figure 11C]. PG-Pt-LA/CB[7] was expected to be a good material for improving the effect of OxPt on CRC cells.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 11. (A) Schematic illustration of the preparation and mechanism of CB[7]-based nanomedicine (PG-Pt-LA/CB[7]) in overcoming drug resistance of CRC cells; (B) Changes of F. nucleatum levels in CRC cells with different treatments; (C) Changes of tumor volume in tumor-bearing mice with different formulations (**P < 0.01, ***P < 0.001). This figure is quoted with permission from Yan et al.[144]. CRC: Colorectal cancer.


Pillararenes (P[n]As) are a new type of macrocyclic hosts that bridge hydroquinone units through methylene discovered by Ogoshi et al. [Figure 1D][145]. These hydroquinone units are generally 5-10, with P[5]A and P[6]A being the most common[146-151]. P[n]As are widely used in various fields such as drug delivery, ion recognition, adsorptive separation, sensors, and optoelectronic materials due to the characteristics of symmetrical rigid skeleton, adjustable electron-rich cavity, and easy functionalization[152-154]. In addition, because of the highly attractive host-guest properties of P[n]As, more and more attention has been paid to the construction of P[n]As-based host-guest nanosystems to overcome cancer drug resistance[155-157]. Liu et al. prepared a novel carboxylatopillar[5]arene-based supramolecular quaternary ammonium nanoparticle to overcome the drug resistance generated during the chemotherapy of CRC[158]. Chang et al. constructed a redox-responsive cationic vesicle based on amphiphilic pillar[5]arene, successfully overcoming the drug resistance of tumors[159].

The water-soluble pillar[6]arene (WP6) not only forms stable host-guest complexes with a variety of guest molecules but also exhibits good biocompatibility and stimuli-responsiveness, which offers the possibility for constructing supramolecular host-guest nanoplatforms to reverse cancer drug resistance[160-166]. Shao et al. reported a host-guest complex (AWP6$$ \supset $$G) containing anionic WP6 (AWP6) and prodrug (G), which further self-assembled to form nanovesicles for inhibiting cancer drug resistance [Figure 12A][167]. The nanovesicles released camptothecin (CPT) and chlorambucil (Cb) under the action of GSH to achieve combination chemotherapy. The dual-drug co-loaded nanovesicles showed a better inhibition effect on drug-resistance cells compared to the single drug [Figure 12B]. This study showed that P[n]As-based supramolecular host-guest nanosystems were expected to be ideal materials for inhibiting MDR.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 12. (A) Schematic illustration of the formation of nanovesicle and its internalization progress; (B) Cell viability of MCF-7 cells after incubation with Cb, CPT, Cb + CPT mixture, and vesicles for 24 h. This figure is quoted with permission from Shao et al.[167]; (C) Schematic illustration of water-solution pillar[6]arene nanosponges (NS) in overcoming MDR; (D) Cell viability of MCF-7/ADR cells after incubation with DOX and DOX@NS. This figure is quoted with permission from Liu et al.[168]; (E) Schematic illustration of the preparation of PIC micelles and their application in inhibiting drug efflux; (F) Changes of extracellular fluorescence intensity after incubating with FA-PEG-b-PAA and different concentrations of PIC micelles; (G) Cell viability of MCF-7/ADR cells after incubation with different treatments. This figure is quoted with permission from Yu et al.[170]. AWP6: Anionic WP6; CPT: camptothecin; DOX: doxorubicin; FA: folic acid; GSH: glutathione; MDR: multidrug resistance; NS: nanosponge; PEG: poly (ethylene glycol); PIC: polyion complex.

Subsequently, Liu et al. prepared a nanosponge (NS) based on AWP6 using a “bottom-up” template preparation technique [Figure 12C][168]. Through the host-guest interaction, antitumor drugs and dyes were stably encapsulated in AWP6 to overcome MDR. The IC50 of DOX@NS (3.4 μM) was significantly lower than that of free DOX (34.4 μM) when different doses of free DOX and DOX-loaded NS were incubated in drug-resistance cells [Figure 12D]. Mechanistic studies indicated that the effective loading and stable encapsulation of DOX based on host-guest interaction were the main reasons for overcoming MDR. This work showed that the delivery of anticancer drugs through host-guest interaction was a promising way to overcome MDR.

Additionally, cationic WP6 (CWP6) can encapsulate ATP, blocking the energy of drug efflux[169]. Yu et al. prepared a polyion complex (PIC) micelle by modifying CWP6 with functionalized diblock copolymer (FA-PEG-b-PAA) [Figure 12E][170]. PIC micelles could specifically target and penetrate cancer cells overexpressed with FA receptors. The decrease in extracellular fluorescence intensity indicated that CWP6 successfully blocked the energy source of calcein (model drug) efflux [Figure 12F]. In addition, PIC micelles significantly enhanced the inhibitory effect of DOX·HCl on cell viability compared with free DOX·HCl [Figure 12G]. These results suggested that the supramolecular nanomicelle endocytosed by drug-resistance cells and released CWP6 to selectively form a host-guest complex with ATP, which provided a new method for blocking the energy of drug efflux and was expected to become an ideal material for overcoming cancer drug resistance.

In addition to blocking the energy source of P-gp expression, nitric oxide (NO) can also downregulate the expression level of P-gp, reversing the drug resistance of cancer[171-173]. To achieve stable delivery and selective release of NO in tumor cells, Ding et al. designed supramolecular peptide nanomedicine (BPC/DOX-ICG) based on the host-guest complexation of anionic water-soluble [2]biphenyl-extended-pillar[6]arene (AWBpP6) with pyridinium-terminal-modified polypeptide (PPNC) [Figure 13A][174]. DOX and indocyanine green (ICG) loaded in BPC/DOX-ICG were used to simultaneously treat cancer cells with chemotherapy and photothermal therapy. S-nitrosothiol on PPNC released NO to downregulate the expression level of P-gp after near-infrared (NIR) irradiation. Western Blot analysis showed that the P-gp level in MCF-7/ADR cells was significantly reduced to 24.9% when treated with NIR irradiation and BPC/DOX-ICG [Figure 13B]. The reduced P-gp could greatly enhance the efficacy of chemotherapeutic drugs, inhibiting tumor growth [Figure 13C]. Therefore, P[n]As-based nanocarriers could effectively deliver NO to downregulate P-gp expression, providing a promising approach to eliminate cancer drug resistance.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 13. (A) Schematic illustration of synergistic PTT and CT using supramolecular polypeptide nanomedicine (BPC/DOX-ICG); (B) The P-gp expression levels in MCF-7/ADR cells with different treatments; (C) Changes of tumor volume in tumor-bearing mice with different formulations (**P < 0.01, ***P < 0.001). This figure is quoted with permission from Ding et al.[174]. DOX: Doxorubicin; ICG: indocyanine green; MDR: multidrug resistance; NIR: near-infrared; PPNC: pyridinium-terminal-modified polypeptide.

Chloride channel protein is highly expressed in various cancer cells and has a significant correlation with tumor drug resistance[175,176]. Yang et al. reported a supramolecular nanoprodrug (DOX@GP5$$ \supset $$Pro-NFA) based on the host-guest complexation between galactose-modified pillar[5]arene (GP5) and chloride channel inhibitor prodrug (Pro-NFA) to reverse drug resistance [Figure 14A][177]. DOX@GP5$$ \supset $$Pro-NFA was hydrolyzed under the action of esterase to release DOX and NFA, which could effectively block chloride ion channels, and reverse cancer drug resistance. Additionally, the inhibitory effect of DOX@GP5$$ \supset $$Pro-NFA on tumor cells, especially drug-resistance cells, was significantly higher than that of free DOX [Figure 14B]. Moreover, poly(ADP ribose)polymerase (PARP) can repair DNA to directly lead to drug resistance[178,179]. Yang et al. designed a nanoparticle (DOX@GP5$$ \supset $$Pro-ANI) based on GP5 to load PARP inhibitor prodrug (Pro-ANI) that could inhibit DNA repair [Figure 14C][180]. DOX@GP5$$ \supset $$Pro-ANI overcame tumor drug resistance by inhibiting the expression of PARP, effectively reducing the viability of drug-resistance cells [Figure 14D]. These studies showed that P[n]As could effectively load anticancer prodrugs, which opened up broad prospects for inhibiting the expression of proteins associated with drug resistance.

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Figure 14. (A) Schematic illustration of the preparation of supramolecular nanoprodrugsDOX@GP5$$ \supset $$Pro-NFA and their applications in overcoming cancer drug resistance; (B) Cell viability of HepG2 cells and HepG2/ADR cells treated with free DOX and DOX@GP5$$ \supset $$Pro-NFA, respectively. This figure is quoted with permission from Yang et al.[177]; (C) Schematic illustration of the preparation of supramolecular nanoprodrugs DOX@GP5$$ \supset $$Pro-ANI and their applications in overcoming cancer drug resistance; (D) Cell viability of HepG2/ADR cells treated with free DOX and DOX@GP5$$ \supset $$Pro-ANI (**P < 0.01). This figure is quoted with permission from Yang et al.[180]. DOX: Doxorubicin; GP5: galactose-modified pillar[5]arene.


In summary, we reviewed the application of supramolecular host-guest nanosystems based on cyclodextrins, calixarenes, cucurbiturils, and pillararenes in overcoming cancer drug resistance. Compared with traditional small molecule drugs, nanosystems can effectively reduce the side effects of drugs and improve the accumulation of drugs in tumors. However, traditional nanosystems also have some drawbacks, such as lack of stimuli-responsiveness, difficulty in preparation and synthesis, and slow degradation in vivo. The emergence of supramolecular nanosystems complements the drawbacks of these traditional nanosystems. Due to their dynamic and reversible host-guest interactions, supramolecular nanosystems are endowed with rich stimuli-responsiveness to release drugs within tumors. Furthermore, supramolecular host-guest nanosystems have some advantages, such as high drug loading, low side effects, and good biocompatibility, which can co-deliver multiple drugs to inhibit cancer drug resistance by damaging mitochondrial function, blocking the energy source, inhibiting DNA repair, and reducing the level of GSH. However, supramolecular host-guest nanosystems still face some challenges in overcoming cancer drug resistance:

(i) Further improve the targeting. Tumor cells differ from healthy cells in many ways, such as acidity, hypoxia, and metabolism. Thus, more specific supramolecular host-guest nanosystems should be developed by focusing on the tumor microenvironment to target and penetrate tumor cells, reversing cancer drug resistance caused by drug uptake;
(ii) Optimize drug loading strategy. Although multidrug-loaded supramolecular host-guest nanosystems can inhibit drug resistance, their effects are difficult to predict due to the different pharmacokinetics of each drug. Therefore, it is necessary to optimize the combination and dosage of loaded drugs and design supramolecular host-guest nanosystems with excellent performances;
(iii) Improve stability. Supramolecular host-guest nanosystems have rich stimuli-responsiveness, but at the same time, there are problems of poor stability. In future studies, the stimuli-responsiveness of supramolecule and the stability of macromolecule can be better combined to prepare supramolecular polymeric nanosystems to overcome cancer drug resistance;
(iv) Promote the development of cancer synergistic therapy. At present, most supramolecular host-guest nanosystems used to overcome drug resistance of tumors remain at the level of drug delivery, which greatly limits the inhibitory effect on drug-resistance cells. Introducing other therapeutic methods (such as photodynamic therapy, gene therapy, and immunotherapy) into supramolecular host-guest nanosystems will help establish more accurate and personalized strategies to combat cancer drug resistance;
(v) Enhance the clinical translation. While some preliminary studies have shown that supramolecular host-guest nanosystems can be used to overcome drug resistance in cancer, there is still a long way to go before clinical translation. Firstly, the pharmacokinetics, biodistribution, metabolic behavior, and toxicological characteristics of supramolecular host-guest nanosystems are still in the research stage, and there are still unpredictable risks to their safety. Secondly, in vitro and in vivo experiments of supramolecular host-guest nanosystems cannot completely mimic the complex microenvironment of tumors in the body, resulting in lower clinical therapeutic effects than expected. Thirdly, the large-scale production of supramolecular host-guest nanosystems is a bottleneck in clinical applications, and small changes in the manufacturing process can cause significant changes in their physicochemical properties, which will affect their safety and biological effects. Therefore, more basic research and clinical trials are needed to assess their safety, efficacy, and feasibility.

The development of supramolecular host-guest nanosystems offers new hope to alleviate drug resistance in cancer, although innovation and progress are still required in many aspects. We believe that with continued research efforts, supramolecular host-guest nanosystems will make further progress in reversing cancer drug resistance, and bring new breakthroughs for cancer treatment and even human health.


Authors’ contributions

Conceptualization: Wu S, Zhou J

Original draft preparation: Wu S

Review and editing: Zhou J, Yan M, Liang M, Yang W, Chen J

Supervision: Zhou J

Availability of data and materials

Not applicable.

Financial support

We thank the National Natural Science Foundation of China (22101043), the Fundamental Research Funds for the Central Universities (N2205013, N232410019), the Open Fund of Guangdong Provincial Key Laboratory of Functional Supramolecular Coordination Materials and Applications (2022A07), and Northeastern University for financial support.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.


© The Author(s) 2023.


1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.

2. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 2020;21:3233.

3. Ward RA, Fawell S, Floc’h N, Flemington V, McKerrecher D, Smith PD. Challenges and opportunities in cancer drug resistance. Chem Rev 2021;121:3297-351.

4. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature 2019;575:299-309.

5. Tiek D, Cheng SY. DNA damage and metabolic mechanisms of cancer drug resistance. Cancer Drug Resist 2022;5:368-79.

6. Wu G, Wilson G, George J, Liddle C, Hebbard L, Qiao L. Overcoming treatment resistance in cancer: current understanding and tactics. Cancer Lett 2017;387:69-76.

7. Aleksakhina SN, Kashyap A, Imyanitov EN. Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer 2019;1872:188310.

8. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18:452-64.

9. Oxnard GR. The cellular origins of drug resistance in cancer. Nat Med 2016;22:232-4.

10. Mullard A. Stemming the tide of drug resistance in cancer. Nat Rev Drug Discov 2020;19:221-3.

11. Liu J, Chen C, Wei T, et al. Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Exploration 2021;1:21-34.

12. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013;12:991-1003.

13. Su Z, Dong S, Zhao SC, et al. Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updat 2021;58:100777.

14. Coombes R. Cancer drug resistance needs urgent attention, says research chief. BMJ 2019;365:l1934.

15. Lehn JM. Supramolecular chemistry: Where from? Where to? Chem Soc Rev 2017;46:2378-9.

16. Zhou J, Yu G, Li Q, Wang M, Huang F. Separation of benzene and cyclohexane by nonporous adaptive crystals of a hybrid[3]arene. J Am Chem Soc 2020;142:2228-32.

17. Tang R, Ye Y, Zhu S, Wang Y, Lu B, Yao Y. Pillar[6]arenes: from preparation, host-guest property to self-assembly and applications. Chinese Chem Lett 2023;34:107734.

18. Yang L, Tan X, Wang Z, Zhang X. Supramolecular polymers: historical development, preparation, characterization, and functions. Chem Rev 2015;115:7196-239.

19. Yu G, Jie K, Huang F. Supramolecular amphiphiles based on host-guest molecular recognition motifs. Chem Rev 2015;115:7240-303.

20. Zhang W, Yang W, Zhou J. Biphenarenes, versatile synthetic macrocycles for supramolecular chemistry. Molecules 2023;28:4422.

21. Hu XY, Gao J, Chen FY, Guo DS. A host-guest drug delivery nanosystem for supramolecular chemotherapy. J Control Release 2020;324:124-33.

22. Wang H, Monroe M, Leslie F, Flexner C, Cui H. Supramolecular nanomedicines through rational design of self-assembling prodrugs. Trends Pharmacol Sci 2022;43:510-21.

23. Wang D, Yu C, Xu L, et al. Nucleoside analogue-based supramolecular nanodrugs driven by molecular recognition for synergistic cancer therapy. J Am Chem Soc 2018;140:8797-806.

24. Chang R, Zou Q, Zhao L, Liu Y, Xing R, Yan X. Amino-acid-encoded supramolecular photothermal nanomedicine for enhanced cancer therapy. Adv Mater 2022;34:2200139.

25. Yan M, Zhou J. Methylene-bridged naphthotubes: new macrocyclic arenes with great potential for supramolecular chemistry. Org Chem Front 2023;10:2340-5.

26. Zhou J, Rao L, Yu G, Cook TR, Chen X, Huang F. Supramolecular cancer nanotheranostics. Chem Soc Rev 2021;50:2839-91.

27. Li Z, Song N, Yang YW. Stimuli-responsive drug-delivery systems based on supramolecular nanovalves. Matter 2019;1:345-68.

28. Wang L, Li L, Fan Y, Wang H. Host-guest supramolecular nanosystems for cancer diagnostics and therapeutics. Adv Mater 2013;25:3888-98.

29. Zhou J, Yu G, Li Y, et al. [2]Pseudorotaxane-based supramolecular optical indicator for the visual detection of cellular cyanide excretion. Chemistry 2019;25:14447-53.

30. Yang X, Wu B, Zhou J, et al. Controlling intracellular enzymatic self-assembly of peptide by host-guest complexation for programming cancer cell death. Nano Lett 2022;22:7588-96.

31. Onishi Y, Eshita Y, Ji RC, et al. Supermolecular drug challenge to overcome drug resistance in cancer cells. Drug Discov Today 2018;23:1556-63.

32. Xu S, Zhu X, Huang W, Zhou Y, Yan D. Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy. J Control Release 2017;266:36-46.

33. Wang Q, Xiao M, Wang D, et al. In situ supramolecular self-assembly of Pt(IV) prodrug to conquer cisplatin resistance. Adv Funct Mater 2021;31:2101826.

34. Yang K, Qi S, Yu X, et al. A hybrid supramolecular polymeric nanomedicine for cascade-amplified synergetic cancer therapy. Angew Chem Int Ed Engl 2022;61:e202203786.

35. Yan M, Zhou J. Suprasomes: an emerging platform for cancer theranostics. Sci China Chem 2023;66:613-4.

36. Sun X, Zhao P, Lin J, Chen K, Shen J. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system. Cancer Drug Resist 2023;6:390-415.

37. Hu T, Gong H, Xu J, Huang Y, Wu F, He Z. Nanomedicines for overcoming cancer drug resistance. Pharmaceutics 2022;14:1606.

38. Ikuta D, Hirata Y, Wakamori S, et al. Conformationally supple glucose monomers enable synthesis of the smallest cyclodextrins. Science 2019;364:674-7.

39. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998;98:1743-54.

40. Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem 2004;39:1033-46.

41. Utzeri G, Matias PMC, Murtinho D, Valente AJM. Cyclodextrin-based nanosponges: overview and opportunities. Front Chem 2022;10:859406.

42. Gandhi S, Shende P. Cyclodextrins-modified metallic nanoparticles for effective cancer therapy. J Control Release 2021;339:41-50.

43. Wankar J, Kotla NG, Gera S, Rasala S, Pandit A, Rochev YA. Recent advances in host-guest self-assembled cyclodextrin carriers: implications for responsive drug delivery and biomedical engineering. Adv Funct Mater 2020;30:1909049.

44. Wang M, Zhou J. Discovery of non-classical complex models between a cationic water-soluble pillar[6]arene and naphthalenesulfonate derivatives and their self-assembling behaviors. Soft Matter 2019;15:4127-31.

45. Fang G, Yang X, Chen S, Wang Q, Zhang A, Tang B. Cyclodextrin-based host-guest supramolecular hydrogels for local drug delivery. Coord Chem Rev 2022;454:214352.

46. Liu Z, Liu Y. Multicharged cyclodextrin supramolecular assemblies. Chem Soc Rev 2022;51:4786-827.

47. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-35.

48. Yuan Y, Nie T, Fang Y, You X, Huang H, Wu J. Stimuli-responsive cyclodextrin-based supramolecular assemblies as drug carriers. J Mater Chem B 2022;10:2077-96.

49. Yang B, Dong X, Lei Q, Zhuo R, Feng J, Zhang X. Host-guest interaction-based self-engineering of nano-sized vesicles for co-delivery of genes and anticancer drugs. ACS Appl Mater Interfaces 2015;7:22084-94.

50. Wang H, Li S, Yang Y, Zhang L, Zhang Y, Wei T. Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance. Cancer Drug Resist 2022;5:954-70.

51. Yu G, Zhao X, Zhou J, et al. Supramolecular polymer-based nanomedicine: high therapeutic performance and negligible long-term immunotoxicity. J Am Chem Soc 2018;140:8005-19.

52. Yang C, Qin Y, Tu K, Xu C, Li Z, Zhang Z. Star-shaped polymer of β-cyclodextrin-g-vitamin E TPGS for doxorubicin delivery and multidrug resistance inhibition. Colloid Surface B 2018;169:10-9.

53. Das M, Nariya P, Joshi A, et al. Carbon nanotube embedded cyclodextrin polymer derived injectable nanocarrier: a multiple faceted platform for stimulation of multi-drug resistance reversal. Carbohydr Polym 2020;247:116751.

54. Mirzaei S, Gholami MH, Hashemi F, et al. Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 2022;27:436-55.

55. Zhang H, Xu H, Ashby CR Jr, Assaraf YG, Chen ZS, Liu HM. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev 2021;41:525-55.

56. Halder J, Pradhan D, Kar B, Ghosh G, Rath G. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomedicine 2022;40:102494.

57. Gottesman MM, Pastan IH. The role of multidrug resistance efflux pumps in cancer: revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. J Natl Cancer Inst 2015;107:djv222.

58. Zhang L, Li Y, Hu C, et al. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. Mol Cancer 2022;21:103.

59. Wang Q, Zou C, Wang L, et al. Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer. Acta Biomater 2019;94:469-81.

60. de Almeida MS, Susnik E, Drasler B, Taladriz-Blanco P, Petri-Fink A, Rothen-Rutishauser B. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev 2021;50:5397-434.

61. Tang G, He J, Liu J, Yan X, Fan K. Nanozyme for tumor therapy: surface modification matters. Exploration 2021;1:75-89.

62. Liu J, Zhao L, Shi L, et al. A sequentially responsive nanosystem breaches cascaded bio-barriers and suppresses P-glycoprotein function for reversing cancer drug resistance. ACS Appl Mater Interfaces 2020;12:54343-55.

63. Brownell JE, Zhou J, Ranalli T, et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996;84:843-51.

64. Sun NK, Kohli A, Huang SL, Chang TC, Chao CCK. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells. J Cell Physiol 2019;234:8760-75.

65. Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther 2020;5:101.

66. Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med 2020;382:2289-301.

67. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11-21.

68. Yuan Y, Liu J, Yu X, et al. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA. Acta Biomater 2021;135:556-66.

69. Koltai T. The complex relationship between multiple drug resistance and the tumor pH gradient: a review. Cancer Drug Resist 2022;5:277-303.

70. Xing S, Hu K, Wang Y. Tumor immune microenvironment and immunotherapy in non-small cell lung cancer: update and new challenges. Aging Dis 2022;13:1615-32.

71. Shi B, Jie K, Zhou Y, Zhou J, Xia D, Huang F. Nanoparticles with near-infrared emission enhanced by pillararene-based molecular recognition in water. J Am Chem Soc 2016;138:80-3.

72. Sa P, Sahoo SK, Dilnawaz F. Responsive role of nanomedicine in the tumor microenvironment and cancer drug resistance. Curr Med Chem 2023;30:3335-55.

73. Wu Y, Li J, Zhong X, et al. A pH-sensitive supramolecular nanosystem with chlorin e6 and triptolide co-delivery for chemo-photodynamic combination therapy. Asian J Pharm Sci 2022;17:206-18.

74. He H, Chen S, Zhou J, et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 2013;34:5344-58.

75. Shi Q, Zhang L, Liu M, et al. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells. Biomaterials 2015;67:169-82.

76. Zhou Z, Guo F, Wang N, Meng M, Li G. Dual pH-sensitive supramolecular micelles from star-shaped PDMAEMA based on β-cyclodextrin for drug release. Int J Biol Macromol 2018;116:911-9.

77. Adeli F, Abbasi F, Babazadeh M, Davaran S. Thermo/pH dual-responsive micelles based on the host-guest interaction between benzimidazole-terminated graft copolymer and β-cyclodextrin-functionalized star block copolymer for smart drug delivery. J Nanobiotechnology 2022;20:91.

78. Yao X, Mu J, Zeng L, et al. Stimuli-responsive cyclodextrin-based nanoplatforms for cancer treatment and theranostics. Mater Horiz 2019;6:846-70.

79. Ren JM, McKenzie TG, Fu Q, et al. Star Polymers. Chem Rev 2016;116:6743-836.

80. Song X, Zhang Z, Zhu J, et al. Thermoresponsive hydrogel induced by dual supramolecular assemblies and its controlled release property for enhanced anticancer drug delivery. Biomacromolecules 2020;21:1516-27.

81. Kost B, Brzeziński M, Cieślak M, et al. Stereocomplexed micelles based on polylactides with β-cyclodextrin core as anti-cancer drug carriers. Eur Polym J 2019;120:109271.

82. Zhou J, Yu G, Yang J, et al. Polymeric nanoparticles integrated from discrete organoplatinum(II) metallacycle by stepwise post-assembly polymerization for synergistic cancer therapy. Chem Mater 2020;32:4564-73.

83. Zhang Y, Yang D, Chen H, et al. Reduction-sensitive fluorescence enhanced polymeric prodrug nanoparticles for combinational photothermal-chemotherapy. Biomaterials 2018;163:14-24.

84. Pawar CS, Rajendra Prasad N, Yadav P, et al. Enhanced delivery of quercetin and doxorubicin using β-cyclodextrin polymer to overcome P-glycoprotein mediated multidrug resistance. Int J Pharm 2023;635:122763.

85. Zhang W, Yang W, Chen J, Wang Y, Yan M, Zhou J. An amphiphilic water-soluble biphen[3]arene with a tunable lower critical solution temperature behavior. New J Chem 2022;46:21453-7.

86. Chen X, Qiu YK, Owh C, Loh XJ, Wu YL. Supramolecular cyclodextrin nanocarriers for chemo- and gene therapy towards the effective treatment of drug resistant cancers. Nanoscale 2016;8:18876-81.

87. Cheng H, Fan X, Wang X, et al. Hierarchically self-assembled supramolecular host-guest delivery system for drug resistant cancer therapy. Biomacromolecules 2018;19:1926-38.

88. Fan X, Cheng H, Wang X, et al. Thermoresponsive supramolecular chemotherapy by “V”-shaped armed β-cyclodextrin star polymer to overcome drug resistance. Adv Healthc Mater 2018;7:1701143.

89. Li W, Xu C, Li S, et al. Cyclodextrin based unimolecular micelles with targeting and biocleavable abilities as chemotherapeutic carrier to overcome drug resistance. Mater Sci Eng C Mater Biol Appl 2019;105:110047.

90. Kumar R, Sharma A, Singh H, et al. Revisiting fluorescent calixarenes: from molecular sensors to smart materials. Chem Rev 2019;119:9657-721.

91. Feng HT, Li Y, Duan X, et al. Substitution activated precise phototheranostics through supramolecular assembly of AIEgen and calixarene. J Am Chem Soc 2020;142:15966-74.

92. Cao S, Zhang H, Zhao Y, Zhao Y. Pillararene/Calixarene-based systems for battery and supercapacitor applications. eScience 2021;1:28-43.

93. Gutsche CD. Calixarenes. Acc Chem Res 1983;16:161-70.

94. Wang J, Ding X, Guo X. Assembly behaviors of calixarene-based amphiphile and supra-amphiphile and the applications in drug delivery and protein recognition. Adv Colloid Interface Sci 2019;269:187-202.

95. Zhou J, Yang J, Zhang Z, Yu G. A cationic water-soluble biphen[3]arene: synthesis, host-guest complexation and fabrication of a supra-amphiphile. RSC Adv 2016;6:77179-83.

96. Zhou J, Yu G, Huang F. Supramolecular chemotherapy based on host-guest molecular recognition: a novel strategy in the battle against cancer with a bright future. Chem Soc Rev 2017;46:7021-53.

97. Chen C, Ni X, Tian HW, Liu Q, Guo DS, Ding D. Calixarene-based supramolecular AIE dots with highly inhibited nonradiative decay and intersystem crossing for ultrasensitive fluorescence image-guided cancer surgery. Angew Chem Int Ed Engl 2020;59:10008-12.

98. Zhang Z, Yue YX, Li Q, et al. Design of calixarene-based ICD inducer for efficient cancer immunotherapy. Adv Funct Mater 2023;33:2213967.

99. Xu L, Chai J, Wang Y, et al. Calixarene-integrated nano-drug delivery system for tumor-targeted delivery and tracking of anti-cancer drugs in vivo. Nano Res 2022;15:7295-303.

100. Liu Q, Zhang TX, Zheng Y, et al. Calixarene-embedded nanoparticles for interference-free gene-drug combination cancer therapy. Small 2021;17:2006223.

101. Fan X, Guo X. Development of calixarene-based drug nanocarriers. J Mol Liq 2021;325:115246.

102. Rahimi M, Karimian R, Noruzi EB, et al. Needle-shaped amphoteric calix[4]arene as a magnetic nanocarrier for simultaneous delivery of anticancer drugs to the breast cancer cells. Int J Nanomedicine 2019;14:2619-36.

103. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 2016;76:7-9.

104. Cheng X, Xu HD, Ran HH, Liang G, Wu FG. Glutathione-depleting nanomedicines for synergistic cancer therapy. ACS Nano 2021;15:8039-68.

105. Xiao X, Wang K, Zong Q, Tu Y, Dong Y, Yuan Y. Polyprodrug with glutathione depletion and cascade drug activation for multi-drug resistance reversal. Biomaterials 2021;270:120649.

106. Gorrini C, Mak TW. Glutathione metabolism: an achilles’ heel of ARID1A-deficient tumors. Cancer Cell 2019;35:161-3.

107. Xiong Y, Xiao C, Li Z, Yang X. Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem Soc Rev 2021;50:6013-41.

108. Ding Y, Dai Y, Wu M, Li L. Glutathione-mediated nanomedicines for cancer diagnosis and therapy. Chem Eng J 2021;426:128880.

109. Dai X, Zhou X, Liao C, Yao Y, Yu Y, Zhang S. A nanodrug to combat cisplatin-resistance by protecting cisplatin with p-sulfonatocalix[4]arene and regulating glutathione S-transferases with loaded 5-fluorouracil. Chem Commun 2019;55:7199-202.

110. Jin P, Jiang J, Zhou L, et al. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol 2022;15:97.

111. Yu G, Wu D, Li Y, et al. A pillar[5]arene-based [2]rotaxane lights up mitochondria. Chem Sci 2016;7:3017-24.

112. Sansone P, Savini C, Kurelac I, et al. Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci U S A 2017;114:E9066-75.

113. Luo X, Gong X, Su L, et al. Activatable mitochondria-targeting organoarsenic prodrugs for bioenergetic cancer therapy. Angew Chem Int Ed Engl 2021;60:1403-10.

114. Nair JB, Joseph MM, Arya JS, Sreedevi P, Sujai PT, Maiti KK. Elucidating a thermoresponsive multimodal photo-chemotherapeutic nanodelivery vehicle to overcome the barriers of doxorubicin therapy. ACS Appl Mater Interfaces 2020;12:43365-79.

115. Mukhopadhyay RD, Kim K. Cucurbituril curiosities. Nat Chem 2023;15:438.

116. Hu JH, Huang Y, Redshaw C, Tao Z, Xiao X. Cucurbit[n]uril-based supramolecular hydrogels: synthesis, properties and applications. Coord Chem Rev 2023;489:215194.

117. Ghosh SK, Dhamija A, Ko YH, et al. Superacid-mediated functionalization of hydroxylated cucurbit[n]urils. J Am Chem Soc 2019;141:17503-6.

118. Fahmy SA, Nematallah KA, Mahdy NK, El-Askary HI, Meselhy MR, El-Said Azzazy HM. Enhanced antioxidant, antiviral, and anticancer activities of the extract of fermented egyptian rice bran complexed with hydroxypropyl-β-cyclodextrin. ACS Omega 2022;7:19545-54.

119. Wu D, Li Y, Yang J, et al. Supramolecular nanomedicine constructed from cucurbit[8]uril-based amphiphilic brush copolymer for cancer therapy. ACS Appl Mater Interfaces 2017;9:44392-401.

120. Wang Z, Sun C, Yang K, Chen X, Wang R. Cucurbituril-based supramolecular polymers for biomedical applications. Angew Chem Int Ed Engl 2022;61:e202206763.

121. You Y, Zhou K, Guo B, et al. Measuring binding constants of cucurbituril-based host-guest interactions at the single-molecule level with nanopores. ACS Sens 2019;4:774-9.

122. Shukla S, Sagar B, Sood AK, Gaur A, Batra S, Gulati S. Supramolecular chemotherapy with cucurbit[n]urils as encapsulating hosts. ACS Appl Bio Mater 2023;6:2089-101.

123. Redondo-Gómez C, Padilla-Lopátegui S, Mata A, Azevedo HS. Peptide amphiphile hydrogels based on homoternary cucurbit[8]uril host-guest complexes. Bioconjug Chem 2022;33:111-20.

124. Barooah N, Mohanty J, Bhasikuttan AC. Cucurbituril-based supramolecular assemblies: prospective on drug delivery, sensing, separation, and catalytic applications. Langmuir 2022;38:6249-64.

125. Liu Z, Lin W, Liu Y. Macrocyclic supramolecular assemblies based on hyaluronic acid and their biological applications. Acc Chem Res 2022;55:3417-29.

126. Li Q, Sun J, Zhou J, Hua B, Shao L, Huang F. Barium cation-responsive supra-amphiphile constructed by a new twisted cucurbit[15]uril/paraquat recognition motif in water. Org Chem Front 2018;5:1940-4.

127. Alabrahim OAA, Fahmy SA, Azzazy HME. Stimuli-responsive cucurbit[n]uril-based supramolecular nanocarriers for delivery of chemotherapeutics. ACS Appl Nano Mater 2023;6:3139-58.

128. Yu Q, Deng T, Lin FC, Zhang B, Zink JI. Supramolecular assemblies of heterogeneous mesoporous silica nanoparticles to co-deliver antimicrobial peptides and antibiotics for synergistic eradication of pathogenic biofilms. ACS Nano 2020;14:5926-37.

129. Safa AR. Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces. Cancer Drug Resist 2022;5:850-72.

130. Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers 2021;13:4363.

131. Sun M, He L, Fan Z, Tang R, Du J. Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis. Biomaterials 2020;257:120252.

132. Janzen DM, Tiourin E, Salehi JA, et al. Retraction note: an apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nat Commun 2020;11:2218.

133. Rainho MA, Siqueira PB, de Amorim ÍSS, Mencalha AL, Thole AA. Mitochondria in colorectal cancer stem cells - a target in drug resistance. Cancer Drug Resist 2023;6:273-83.

134. Chen W, Shi K, Chu B, Wei X, Qian Z. Mitochondrial surface engineering for multidrug resistance reversal. Nano Lett 2019;19:2905-13.

135. Zhou J, Hua B, Shao L, Feng H, Yu G. Host-guest interaction enhanced aggregation-induced emission and its application in cell imaging. Chem Commun 2016;52:5749-52.

136. Dai XY, Zhang B, Yu Q, Liu Y. In situ coassembly induced mitochondrial aggregation activated drug-resistant tumor treatment. J Med Chem 2022;65:7363-70.

137. Kroll T, Prescher M, Smits SHJ, Schmitt L. Structure and function of hepatobiliary ATP binding cassette transporters. Chem Rev 2021;121:5240-88.

138. Goebel J, Chmielewski J, Hrycyna CA. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors. Cancer Drug Resist 2021;4:784-804.

139. Wang H, Wu H, Yi Y, et al. Self-motivated supramolecular combination chemotherapy for overcoming drug resistance based on acid-activated competition of host-guest interactions. CCS Chem 2021;3:1413-25.

140. Zhao T, Wang X, Fu L, Yang K. Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response. Cancer Drug Resist 2022;5:436-50.

141. Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol 2019;17:156-66.

142. Wang N, Fang JY. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol 2023;31:159-72.

143. Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist 2023;6:257-72.

144. Yan X, Ma F, Chen Q, et al. Construction of size-transformable supramolecular nano-platform against drug-resistant colorectal cancer caused by Fusobacterium nucleatum. Chem Eng J 2022;450:137605.

145. Ogoshi T, Kanai S, Fujinami S, Yamagishi TA, Nakamoto Y. para-Bridged symmetrical pillar[5]arenes: their Lewis acid catalyzed synthesis and host-guest property. J Am Chem Soc 2008;130:5022-3.

146. Sun J, Hua B, Li Q, Zhou J, Yang J. Acid/base-controllable FRET and self-assembling systems fabricated by rhodamine B functionalized pillar[5]arene-based host-guest recognition motifs. Org Lett 2018;20:365-8.

147. Yan M, Zhou J. Pillararene-based supramolecular polymers for cancer therapy. Molecules 2023;28:1470.

148. Song N, Kakuta T, Yamagishi T, Yang YW, Ogoshi T. Molecular-scale porous materials based on pillar[n]arenes. Chem 2018;4:2029-53.

149. Wang J, Wang D, Cen M, et al. GOx-assisted synthesis of pillar[5]arene based supramolecular polymeric nanoparticles for targeted/synergistic chemo-chemodynamic cancer therapy. J Nanobiotechnology 2022;20:33.

150. Wang C, Li H, Dong J, et al. Pillararene-based supramolecular vesicles for stimuli-responsive drug delivery. Chemistry 2022;28:e202202050.

151. Zhu W, Li E, Zhou J, Zhou Y, Sheng X, Huang F. Highly selective removal of heterocyclic impurities from toluene by nonporous adaptive crystals of perethylated pillar[6]arene. Mater Chem Front 2020;4:2325-9.

152. Wang M, Fang S, Yang S, et al. Separation of ethyltoluene isomers by nonporous adaptive crystals of perethylated and perbromoethylated pillararenes. Mater Today Chem 2022;24:100919.

153. Yang W, Zhang W, Chen J, Zhou J. Mono-functionalized pillar[n]arenes: syntheses, host-guest properties and applications. Chinese Chem Lett 2024;35:108740.

154. Wang Y, Wang D, Wang J, et al. Pillar[5]arene-derived covalent organic materials with pre-encoded molecular recognition for targeted and synergistic cancer photo- and chemotherapy. Chem Commun 2022;58:1689-92.

155. Zhou J, Yu G, Shao L, Hua B, Huang F. A water-soluble biphen[3]arene: synthesis, host-guest complexation, and application in controllable self-assembly and controlled release. Chem Commun 2015;51:4188-91.

156. Zhou L, Cao S, Liu C, Zhang H, Zhao Y. Pillar[n]arene-based polymeric systems for biomedical applications. Coord Chem Rev 2023;491:215260.

157. Li Q, Li X, Ning L, Tan CH, Mu Y, Wang R. Hyperfast water transport through biomimetic nanochannels from peptide-attached (pR)-pillar[5]arene. Small 2019;15:1804678.

158. Liu H, Yang J, Yan X, et al. A dendritic polyamidoamine supramolecular system composed of pillar[5]arene and azobenzene for targeting drug-resistant colon cancer. J Mater Chem B 2021;9:9594-605.

159. Chang Y, Yang K, Wei P, et al. Cationic vesicles based on amphiphilic pillar[5]arene capped with ferrocenium: a redox-responsive system for drug/siRNA co-delivery. Angew Chem Int Ed Engl 2014;53:13126-30.

160. Wang M, Zhou J, Li E, Zhou Y, Li Q, Huang F. Separation of monochlorotoluene isomers by nonporous adaptive crystals of perethylated pillar[5]arene and pillar[6]arene. J Am Chem Soc 2019;141:17102-6.

161. Wang Y, Pei Z, Feng W, Pei Y. Stimuli-responsive supramolecular nano-systems based on pillar[n]arenes and their related applications. J Mater Chem B 2019;7:7656-75.

162. Liu X, Jia K, Wang Y, et al. Dual-responsive bola-type supra-amphiphile constructed from water-soluble pillar[5]arene and naphthalimide-containing amphiphile for intracellular drug delivery. ACS Appl Mater Interfaces 2017;9:4843-50.

163. Wang M, Li Q, Li E, Liu J, Zhou J, Huang F. Vapochromic behaviors of a solid-state supramolecular polymer based on exo-wall complexation of perethylated pillar[5]arene with 1,2,4,5-tetracyanobenzene. Angew Chem Int Ed Engl 2021;60:8115-20.

164. Yang K, Wen J, Chao S, et al. A supramolecular photosensitizer system based on the host-guest complexation between water-soluble pillar[6]arene and methylene blue for durable photodynamic therapy. Chem Commun 2018;54:5911-4.

165. Bai Y, Liu C, Yang J, Liu C, Shang Q, Tian W. Supramolecular self-assemblies based on water-soluble pillar[6]arene and drug-drug conjugates for the combination of chemotherapy. Colloid Surface B 2022;217:112606.

166. Yu G, Zhou J, Chi X. Pillar[10]arene-based size-selective host-guest complexation and its application in tuning the LCST behavior of a thermoresponsive polymer. Macromol Rapid Commun 2015;36:23-30.

167. Shao W, Liu X, Sun G, Hu XY, Zhu JJ, Wang L. Construction of drug-drug conjugate supramolecular nanocarriers based on water-soluble pillar[6]arene for combination chemotherapy. Chem Commun 2018;54:9462-5.

168. Liu Y, Liao Y, Li P, Li ZT, Ma D. Cross-linked pillar[6]arene nanosponges fabricated by the use of a supra-amphiphilic template: cargo encapsulation and overcoming multidrug resistance. ACS Appl Mater Interfaces 2020;12:7974-83.

169. Zhou J, Chen M, Diao G. Synthesis of the first amphiphilic pillar[6]arene and its enzyme-responsive self-assembly in water. Chem Commun 2014;50:11954-6.

170. Yu G, Zhou J, Shen J, Tang G, Huang F. Cationic pillar[6]arene/ATP host-guest recognition: selectivity, inhibition of ATP hydrolysis, and application in multidrug resistance treatment. Chem Sci 2016;7:4073-8.

171. Yao X, Yang B, Xu J, He Q, Yang W. Novel gas-based nanomedicines for cancer therapy. VIEW 2022;3:20200185.

172. Deng Y, Jia F, Chen X, Jin Q, Ji J. ATP suppression by pH-activated mitochondria-targeted delivery of nitric oxide nanoplatform for drug resistance reversal and metastasis inhibition. Small 2020;16:2001747.

173. Zhou J, Yang J, Hua B, Shao L, Zhang Z, Yu G. The synthesis, structure, and molecular recognition properties of a [2]calix[1]biphenyl-type hybrid[3]arene. Chem Commun 2016;52:1622-4.

174. Ding Y, Ma Y, Zhu L, et al. Nitric oxide-containing supramolecular polypeptide nanomedicine based on [2]biphenyl-extended-pillar[6]arenes for drug resistance reversal. J Mater Chem B 2022;10:6181-6.

175. Valverde MA, Díaz M, Sepúlveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 1992;355:830-3.

176. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepúlveda FV. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 1992;71:23-32.

177. Yang K, Ma K, Yang M, Lv Y, Pei Y, Pei Z. Supramolecular nanoprodrug based on a chloride channel blocker and glycosylated pillar[5]arenes for targeted chemoresistance cancer therapy. Chem Commun 2023;59:3779-82.

178. van Waardenburg RCAM, Yang ES. Targeting DNA repair pathways to overcome cancer drug resistance. Cancer Drug Resist 2021;4:837-41.

179. Nickoloff JA, Taylor L, Sharma N, Kato TA. Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy. Cancer Drug Resist 2021;4:244-63.

180. Yang M, Yang K, Gao B, et al. A supramolecular nano-delivery system based on AIE PARP inhibitor prodrug and glycosylated pillar[5]arene for drug-resistance therapy. Chem Commun 2022;58:11147-50.

Cite This Article

OAE Style

Wu S, Yan M, Liang M, Yang W, Chen J, Zhou J. Supramolecular host-guest nanosystems for overcoming cancer drug resistance. Cancer Drug Resist 2023;6:805-27.

AMA Style

Wu S, Yan M, Liang M, Yang W, Chen J, Zhou J. Supramolecular host-guest nanosystems for overcoming cancer drug resistance. Cancer Drug Resistance. 2023; 6(4): 805-27.

Chicago/Turabian Style

Wu, Sha, Miaomiao Yan, Minghao Liang, Wenzhi Yang, Jingyu Chen, Jiong Zhou. 2023. "Supramolecular host-guest nanosystems for overcoming cancer drug resistance" Cancer Drug Resistance. 6, no.4: 805-27.

ACS Style

Wu, S.; Yan M.; Liang M.; Yang W.; Chen J.; Zhou J. Supramolecular host-guest nanosystems for overcoming cancer drug resistance. Cancer Drug Resist. 2023, 6, 805-27.

About This Article

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (, which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Data & Comments




Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at

Download PDF
Cite This Article 12 clicks
Like This Article 13 likes
Share This Article
Scan the QR code for reading!
See Updates
Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: